ReviewCurrent hypertension reports2002
Peroxisome proliferator-activated receptor gamma and atherosclerosis.
Review in Current hypertension reports, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 23 citations in OpenAlex.
- Role of PPARs in Trypanosoma cruzi Infection: Implications for Chagas Disease Therapy.PPAR research · 2012Article
- CD40/CD40L system and vascular disease.Internal and emergency medicine · 2007Review
- The vascular biology of peroxisome proliferator-activated receptors: modulation of atherosclerosis.The Canadian journal of cardiology · 2006Review
- Inhibition of vascular inflammation by dehydroepiandrosterone sulfate in human aortic endothelial cells: roles of PPARalpha and NF-kappaB.Vascular pharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Within the past couple of years, peroxisome proliferator-activated receptor gamma (PPARgamma), a nuclear transcription factor expressed in vascular cells, has received growing interest in vascular biology and atherosclerosis research. Initially, PPARgamma was identified as a regulator of gene expression in lipid metabolism and adipogenesis, but recent data in monocyte/macrophages, endothelial cells, and vascular smooth muscle cells suggest that PPARgamma might have anti-inflammatory effects in atherogenesis. However, with growing insight, there is much controversy about potential anti- or proatherosclerotic effects. This review will focus on these aspects and discuss what PPARgamma activation in vascular cells could mean for atherogenesis and the development of atherosclerosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.